Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2015 | Pages:
55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Genmab A/S - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Genmab A/S - Product Pipeline Review - 2015', provides an overview of the Genmab A/S's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Genmab A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Genmab A/S including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Genmab A/S's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Genmab A/S's pipeline products Reason To Buy - Evaluate Genmab A/S's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Genmab A/S in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Genmab A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Genmab A/S and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Genmab A/S - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Genmab A/S and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Genmab A/S Snapshot 6 Genmab A/S Overview 6 Key Information 6 Key Facts 6 Genmab A/S - Research and Development Overview 7 Key Therapeutic Areas 7 Genmab A/S - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Pipeline Products - Out-Licensed Products 14 Out-Licensed Products/Combination Treatment Modalities 15 Genmab A/S - Pipeline Products Glance 16 Genmab A/S - Late Stage Pipeline Products 16 Phase III Products/Combination Treatment Modalities 16 Genmab A/S - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 Genmab A/S - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Genmab A/S - Drug Profiles 20 ofatumumab 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 teprotumumab 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 HuMax-TF-ADC 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 DuoBody Cancer-5 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 DuoBody Cancer-6 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 EM1-mAb 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Humax Cancer-3 ADC 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 HuMax-AXL-ADC 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 HuMax-TAC-ADC 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 IDD-004 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Monoclonal Antibodies for Central Nervous System, Infectious Disease, Oncology and Autoimmune Disorders 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Monoclonal Antibody 1 for Central Nervous System Disorders 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Monoclonal Antibody 2 for Central Nervous System Disorders 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Monoclonal Antibody 3 for Central Nervous System Disorders 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 TF-011 Monomethyl Auristatin E 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Genmab A/S - Pipeline Analysis 40 Genmab A/S - Pipeline Products by Target 40 Genmab A/S - Pipeline Products by Route of Administration 41 Genmab A/S - Pipeline Products by Molecule Type 42 Genmab A/S - Pipeline Products by Mechanism of Action 43 Genmab A/S - Recent Pipeline Updates 44 Genmab A/S - Dormant Projects 49 Genmab A/S - Discontinued Pipeline Products 50 Discontinued Pipeline Product Profiles 50 HuMax-CD74-ADC 50 ofatumumab 50 teprotumumab 50 Genmab A/S - Company Statement 51 Genmab A/S - Locations And Subsidiaries 53 Head Office 53 Other Locations & Subsidiaries 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables
Genmab A/S, Key Information 6 Genmab A/S, Key Facts 6 Genmab A/S - Pipeline by Indication, 2015 8 Genmab A/S - Pipeline by Stage of Development, 2015 10 Genmab A/S - Monotherapy Products in Pipeline, 2015 11 Genmab A/S - Partnered Products in Pipeline, 2015 12 Genmab A/S - Partnered Products/ Combination Treatment Modalities, 2015 13 Genmab A/S - Out-Licensed Products in Pipeline, 2015 14 Genmab A/S - Out-Licensed Products/ Combination Treatment Modalities, 2015 15 Genmab A/S - Phase III, 2015 16 Genmab A/S - Phase II, 2015 17 Genmab A/S - Phase I, 2015 18 Genmab A/S - Preclinical, 2015 19 Genmab A/S - Pipeline by Target, 2015 40 Genmab A/S - Pipeline by Route of Administration, 2015 41 Genmab A/S - Pipeline by Molecule Type, 2015 42 Genmab A/S - Pipeline Products by Mechanism of Action, 2015 43 Genmab A/S - Recent Pipeline Updates, 2015 44 Genmab A/S - Dormant Developmental Projects,2015 49 Genmab A/S - Discontinued Pipeline Products, 2015 50 Genmab A/S, Subsidiaries 53
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
